Fluoxetine (Prozac) augments platelet activation mediated through protease-activated receptors [3]

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 4, 2008, Pages 705-708

  Dilks, J R ^a   Flaumenhaft, Robert ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; CD63 ANTIGEN; FLUOXETINE; METHYSERGIDE; PADGEM PROTEIN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 4; SEROTONIN; SEROTONIN 2A RECEPTOR; THROMBIN;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; CARDIOVASCULAR RISK; CONCENTRATION RESPONSE; DRUG INHIBITION; DRUG MECHANISM; HEART PROTECTION; HUMAN; LETTER; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOGENESIS;

ADENINE; ANTIGENS, CD; BLOOD PLATELETS; CYTOPLASMIC GRANULES; DRUG SYNERGISM; FLUOXETINE; HUMANS; METHYSERGIDE; OLIGOPEPTIDES; P-SELECTIN; PEPTIDE FRAGMENTS; PLATELET ACTIVATION; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTOR, PAR-1; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, PURINERGIC P2; RECEPTORS, THROMBIN; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; THROMBIN; VALERATES;

EID: 40949165262     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.02896.x     Document Type: Letter

References (11)

1. Walther DJ, Peter JU, Winter S, Holtje M, Paulmann N, Grohmann M, Vowinckel J, Alamo-Bethencourt V, Wilhelm CS, Ahnert-Hilger G, Bader M. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell 2003; 115: 851-62.
2. Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci 2007; 9: 47-59.
3. de Abajo FJ, Montero D, Rodriguez LA, Madurga M. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol 2006; 98: 304-10.
4. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003; 108: 32-6.
5. Tata LJ, West J, Smith C, Farrington P, Card T, Smeeth L, Hubbard R. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart 2005; 91: 465-71.
6. Kurne A, Ertugrul A, Anil Yagcioglu AE, Yazici KM. Venous thromboembolism and escitalopram. Gen Hosp Psychiatry 2004; 26: 481-3.
7. Scordo MG, Spina E, Dahl ML, Gatti G, Perucca E. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol 2005; 97: 296-301.
8. Harper CM, Fukodome T, Engel AG. Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology 2003; 60: 1710-3.
9. Kim S, Foster C, Lecchi A, Quinton TM, Prosser DM, Jin J, Cattaneo M, Kunapuli SP. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. Blood 2002; 99: 3629-36.
10. Tharmapathy P, Fukami MH, Holmsen H. The stimulatory effects of cationic amphiphilic drugs on human platelets treated with thrombin. Biochem Pharmacol 2000; 60: 1267-77.
11. Momo F, Fabris S, Stevanato R. Interaction of fluoxetine with phosphatidylcholine liposomes. Biophys Chem 2005; 118: 15-21.